Association of nonmalignant portal vein thrombosis and clinical outcomes in patients with cirrhosis and acute variceal bleeding: a multicenter observational study
Yong Lv,Wei Bai,Xuan Zhu,Hui Xue,Jianbo Zhao,Yuzheng Zhuge,Junhui Sun,Chunqing Zhang,Pengxu Ding,Zaibo Jiang,Xiaoli Zhu,Weixin Ren,Yingchun Kewei LiZhang,Wenguang Zhang,Kai Li,Zhengyu Wang,Bohan Luo,Xiaomei Li,Jie Yuan,Zhiping Yang,Wengang Guo,Dongdong Xia,Huahong Xie,Changbing Yang,Yanglin Pan,Zhanxin Yin,Daiming Fan,Guohong Han
DOI: https://doi.org/10.1007/s12072-023-10493-1
IF: 9.029
2023-05-31
Hepatology International
Abstract:Background and aimBaveno VII workshop recommends management of acute variceal bleeding (AVB) in cirrhotic patients with nonmalignant portal vein thrombosis (PVT) should be performed according to the guidelines for patients without PVT. Nevertheless, whether PVT affects the outcome of patients with cirrhosis and AVB remains unclear. The aim of this study was to assess the clinical impact of PVT on the outcomes in the pre-emptive TIPSS eligible patients with cirrhosis and AVB.MethodsFrom December 2010 to June 2016, 1219 consecutive cirrhotic patients admitted due to AVB with (n = 151; 12.4%) or without PVT (n = 1068; 87.6%), who received drug plus endoscopic treatment (a combination of vasoactive drugs, antibiotics, and endoscopic ligation for AVB, followed by beta-blockers plus variceal ligation for prevention of rebleeding) were retrospectively included. Fine and Gray competing risk regression models were taken to evaluate the impact of PVT on clinical outcomes after adjusting for potential confounders.ResultsDuring follow-up, 211 patients (17.3%) died, 490 (40.2%) experienced further bleeding, and 78 (6.4%) experienced new or worsening ascites within 1 year. Compared with those without PVT, patients with PVT had a similar risk of mortality (PVT vs no-PVT: 19.9% vs 16.7% at 1 year; adjusted HR 0.88, 95%CI 0.51–1.52, p = 0.653), further bleeding (47.0% vs 39.2% at 1 year, adjusted HR 1.19, 95% CI 0.92–1.53, p = 183), and new or worsening ascites (7.9% vs 9.6%, adjusted HR 0.70, 95% CI 0.39–1.28, p = 0.253) after adjusting for confounders in multivariable models. These findings were consistent across different relevant subgroups and confirmed by propensity score matching analysis.ConclusionsOur study showed no evidence that the PVT was associated with an improved or worsened outcome among cirrhotic patients with AVB who received standard treatment.Graphical abstract
gastroenterology & hepatology